Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03413579
Other study ID # CIMA-I3-05D143-01
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 2015
Est. completion date February 2021

Study information

Verified date March 2020
Source El Kendi Pharmaceuticals Manufacturing Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the present study is to estimate the overall survival of patients with cervical cancer after the administration of monoclonal antibody (mAb) Nimotuzumab (hR3) in combination with chemotherapy of first intention. Patients will be randomized in two parallel treatment groups. The first group will receive a dose of 200 mg of monoclonal antibody anti-hR3 (weekly during 18 weeks), combined with a chemotherapy (6 cycles, every 21 days of Cisplatin 70mg/m2, Vinorelbine 60 mg/m2 (Per Os) at D1 and D8 and then 80mg / m2. The second group will receive a placebo in combination with the same chemotherapy regimen as the first group. At the end of the first intention chemotherapy treatment, a dose of maintenance of Nimotuzumab will be administered at the dose of 200mg every 14 days until progression. A second chemotherapy in the second intention is proposed, this one is based on Carboplatin ( CBP) in an AUC (area under curve) of 6, and Paclitaxel (Txl) in 175 mg / m2 / BSA (body surface area ) in drip of 3 hours, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a limit of toxicity or an ECOG (Eastern Cooperative Oncology Group) status superior to 3, appears.


Description:

The objective of the present study is to assess the overall survival of patients after administration of Nimotuzumab hR3 monoclonal antibodies (combined with a chemotherapy) in the treatment of patients with cervix epithelial tumors as first-line treatment. The patients included will be divided into two treatment groups. The first group receive a 200 mg dose of hR3 monoclonal antibody (weekly for 18 weeks), and chemotherapy (6 cycles, every 21 days: Cisplatin (CDDP) 70 mg / m2 on day 1, Vinorelbine 60 mg / m2 on day 1 and day 8) and then 80mg / m2. The second group receive a placebo in addition to the listed chemotherapy. After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress. A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears. The survival overall will be considered as the main variable of the response and survival without progression from the antitumor response, the toxicity assessment and the quality of life will be the secondary variables. In addition, the effects may arise during treatment will be identified, and tumor biopsy markers such as, EGF-R and HPV will be determined and those of p53, Ki67 and Bcl-2 by immunohistochemistry (IHC). It is expected to achieve a difference in survival between the treatment groups of 6.5 vs 10.5 months (0.278 vs 0.62) in favor of the group with mAb hR3.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date February 2021
Est. primary completion date March 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients aged between 18 to 75, including both limits. - Patients who give their written consent to participate to the study. - Chemonaive patients with local cervical cancer and / or persistent or recurrent metastatic disease with measurable disease (RECIST criteria) by a physical examination (scanner or MRI). A confirmation by biopsy is necessary in case there is a single lesion less than 2 cm. - Patients who had pelvic CT + radiotherapy may also be included in the study (concomitant chemotherapy as a radiotherapy stabilizer). - Patients having a histopathological report: epidermoid carcinoma, adenocarcinoma, adenosquamous carcinoma and / or clear cells carcinoma. - Patients with an ECOG score between 0-2 - Patients with a life expectancy greater than six months. - Patients with Left Ventricular Ejection Fraction (LVEF) =50%, through Echocardiography. - Patients with normal function of organs and bone marrow, defined by the following parameters: - Haemoglobin = 9 g / dL - White Blood cell = 4000 /mm3 - Absolute neutrophil count= 1500 /mm3 - Platelet count= 100000 /mm3 - Total bilirubin up to 1.5 the upper limit of normal (ULN) - Albumin = 2 g/dL (3,5 - 5,0 g /dl) - Serum Glutamopyruvate Transférase (SGPT) and SErum Glutamooxaloacetate Transferase (SGTO) < or = 2.5 ULN - Serum creatinine within the normal limits and the calculation of glomerular filtration according to Cockcroft formula = 60ml and according to MDRD formula for patients whose age is 70 years = 60ml . Glomerular filtration will be performed only on clinical discretion for patients suspected to have a kidney problem. (The normal laboratory values will be appropriate to the techniques and equipment used in the place where they are done). - The determination or expression of EGF-R (epidermal growth factor receptor), p53, Ki67 and Bcl-2 by immuno-histochemistry in the primary tumor before treatment integrated in a paraffin block. The results are not an inclusion criterion, but will be evaluated as an indicator of prognostic response in the final assessment. Exclusion Criteria: - Pregnant or breastfeeding patients - Patients with small cells and / or neuroendocrine cervical cancer. - Patients receiving another onco-specific drug, for other clinical trial, - Patients with a history of allergy attributed to chemical or biological compounds similar to the monoclonal antibody being evaluated or to chemotherapeutic agents. - Patients having uncontrolled intercurrent diseases, including active infections, symptomatic congestive heart failure , unstable angina, cardiac arrhythmia, decompensated diabetes, uncontrolled hypertension and psychiatric disorders. - Patients having a second tumor . Excepting for those receiving appropriate therapy for skin cancer (basal or squamous) - Previous or concomitant malignancy with exception for non-melanoma skin carcinomas - Patients having special conditions or circumstances that could significantly limit the complete follow up of the study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Nimotuzumab ( h-R3)
Humanized monoclonal antibody
Other:
Placebo


Locations

Country Name City State
Algeria Centre Pierre et Marie Curie (CPMC) Algiers
Algeria CAC Annaba Annaba
Algeria CAC Batna Batna
Algeria CHU Frantz Fanon Blida
Algeria CHU Sidi Belloua Tizi Ouzou

Sponsors (1)

Lead Sponsor Collaborator
El Kendi Pharmaceuticals Manufacturing Company

Country where clinical trial is conducted

Algeria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival in patients who received hR3 mAb treatment combined with Chemotherapy Calculated from patient randomisation to death (36 months)
Secondary Antitumor Response up to 24months (every 3 months)
Secondary Duration of response from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Secondary Time to progression Time from randomization until objective tumor progression assessed up to 60 months
Secondary Progression-free survival Time from randomization until disease progression or death, assessed up to 60 months
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A